AGIO — AGIOS PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1439222 ·
Last close
$30.02
Market Cap
$1.79B
52W High
$44.09
52W Low
$26.44
ADV30
1,285,097
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 44,745,000 | 41,749,000 | -110,552,000 | -100,703,000 | 1,108,424,000 | 99,647,000 | 82,403,000 |
| Mar 2026 | 20,746,000 | 19,427,000 | -110,025,000 | -99,111,000 | 1,184,990,000 | 113,600,000 | 75,875,000 |
| Dec 2025 | 19,967,000 | 18,088,000 | -121,578,000 | -108,039,000 | 1,297,225,000 | 89,130,000 | 104,111,000 |
| Sep 2025 | 12,880,000 | 11,201,000 | -116,869,000 | -103,433,000 | 1,385,705,000 | 92,710,000 | 101,375,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-360,596,000
Investing CF
$367,153,000
Financing CF
$12,219,000
CapEx
$-29,656,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.09
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-761,519,000
Inventory
$30,152,000
Receivables
$24,216,000
ST Investments
$517,929,000
EBIT TTM
$-459,024,000
Pretax Income TTM
$-412,302,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$98,338,000
EBITDA
$-453,671,008
Free Cash Flow
$-274,604,000
Enterprise Value
$1,205,845,504
Total Cash
$617,576,000
Total Debt
$31,171,000
Shares Out
59,701,882
Trailing EPS
$-7.01
Book Value
$20.41
ROE
-34.3%
ROA
-22.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 54,028,000 | -472,132,000 | -412,781,000 | 1,297,225,000 | 104,111,000 | — | -372,977,000 |
| Dec 2024 | 36,498,000 | -425,737,000 | 673,725,000 | 1,663,199,000 | 122,243,000 | — | -389,841,000 |
| Dec 2023 | 26,823,000 | -391,487,000 | -352,088,000 | 937,118,000 | 126,099,000 | — | -296,062,000 |
| Dec 2022 | 14,240,000 | -389,047,000 | -231,801,000 | 1,238,718,000 | 137,904,000 | — | -309,478,000 |
TTM Snapshot
Revenues TTM
$19,879,000
NetIncome TTM
$686,078,000
OpCashFlow TTM
$0
Assets (Latest)
$1,663,199,000
Forward EPS
$-4.30
Max Pain — expiry 2026-12-18
max pain strike: $25.00 · spot: $30.02 · call oi: 29,283 · put oi: 664
Expected Move to 2026-12-18:
±$9.60
(31.98%) —
implied range
$20.42 –
$39.62
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GENB | Generate Biomedicines, Inc. | $1.79B | $14.00 | — |
| OCUL | OCULAR THERAPEUTIX, INC | $1.79B | $8.17 | — |
| STOK | Stoke Therapeutics, Inc. | $1.80B | $28.86 | — |
| DMRA | Damora Therapeutics, Inc. | $1.78B | $28.99 | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.80B | $79.24 | — |
News headlines (Yahoo Finance, 1h cache)
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
2026-07-31 16:17 · Yahoo
Agios Pharmaceuticals Inc (AGIO) (Q2 2026) Earnings Call Highlights: Strong Mitapivat Revenue ...
2026-07-30 19:02 · Yahoo
Agios Pharmaceuticals Q2 Earnings Call Highlights
2026-07-30 14:04 · Yahoo
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
2026-07-30 11:50 · Yahoo
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-30 10:30 · Yahoo
Tebapivat Sickle Cell Setback and Mitapivat Priority Review Could Be A Game Changer For Agios (AGIO)
2026-07-30 00:14 · Yahoo
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals
2026-07-28 08:58 · Yahoo
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
2026-07-27 16:36 · Yahoo
Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards?
2026-07-27 15:11 · Yahoo
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
2026-07-23 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.